Driving pharma research with AdisInsight
Jinfo Blog
20th March 2017
Abstract
Is there a database that can provide information across the whole drug lifecycle, from profiles of drugs in development, insights into clinical trials and how these advance drugs through to regulatory pathways, to safety reports associated with a drug, and current deals with the organisations involved? We see how AdisInsight stacks up.
Item
The AdisInsight database from Adis, a Springer Nature company, has been upgraded following feedback from customers. We recently looked at those improvements in "Mini review of AdisInsight - a 'one-stop solution' for pharmaceutical researchers".
The database has been upgraded to improve the customer's experience of gathering information on all the areas the platform offers - scientific information on drugs in commercial development, key clinical trials, deals, and safety profiles. The improvements add to what was already an innovative offering when first reviewed by Jinfo in 2015.
Jinfo contributor Dr Michelle Maxwell gives you a step by step guide to how the new platform performs and the technology that drives it.
She writes, "The search functionality continues to evolve with the introduction of new search parameters, structure search and the ability to see your last five searches. The export options have improved and now let you cherry-pick data and print in grid view. The interface has improved with increased options in the left-hand column and the inclusion of various filters to narrow down searches."
Improved experience and enriched content
To achieve some of these changes, Adis has teamed up with Amplion, a market leader in biomarker information. The partnership has helped "to enrich drug and clinical trial content in the AdisInsight platform with curated biomarker data. The new data is fully integrated into the AdisInsight platform, meaning that users can perform quick or advanced searches across the data, view biomarker information within drug and trial profiles, and include it with exports and alerts", writes Michelle.
The improvements to the platform have come following feedback from Adis customers, typically research scientists, clinicians, procurement and venture capitalists. All have different requirements for their information research and analysis.
According to the review, "The improved search functionality and ability to search by structure has helped the research community get the results they need more quickly. Improvements to the export options, to support various file formats, have made it easier to share data on the platform. This is very important when looking for opportunities for deals, drug regulatory panels and when looking for a gap in the market."
Find out more
The AdisInsight platform may still at first sight look like the version launched in 2015 but technologically it has changed. To find out how far the changes go, why not take a look at "Mini review of AdisInsight - a 'one-stop solution' for pharmaceutical researchers".
- Blog post title: Driving pharma research with AdisInsight
- Link to this page
- View printable version
- Mini review of AdisInsight - a "one-stop solution" for pharmaceutical researchers
Wednesday, 15th March 2017 - Revolutionising big pharma with big data, visualisation and analytics
Friday, 25th November 2016
- Market landscape - the leaders in big pharma data visualisation
Friday, 25th November 2016
Community session
11th December 2024
2025 strategic planning; evaluating research reports; The Financial Times, news and AI
5th November 2024
How are information managers getting involved with AI? Navigating privacy, ethics, and intellectual property
- 2025 strategic planning; evaluating research reports; The Financial Times, news and AI
5th November 2024 - All recent Jinfo Subscription content
31st October 2024 - End-user training best practice research
24th October 2024
- Jinfo Community session (TBC) (Community) 23rd January 2025
- Clinic on contracting for AI (Community) 11th December 2024
- Discussing news and AI strategies with the Financial Times (Community) 21st November 2024